Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Benefits of apixaban among venous thromboembolism patients with active cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.19
Views: 1883
Rating:

Dr Alexander Cohen - Guys and St Thomas, London, UK

Dr Alexander Cohen speaks to ecancer at the ASH 2019 meeting in Orlando about the data he was presenting on the safety and effectiveness of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer.

He says the observational study found that there was a lower rate of major bleeding and reduced recurrences of venous thromboembolism in patients who were treated with apixaban.

Dr Cohen comments that this is good news for patients who tend to prefer oral therapies to injectable therapies. There are also greater adherence and persistence rates with oral therapies, which results in better outcomes.

With regards to next steps, Dr Cohen explains that the optimal length of anticoagulant therapy is still unknown.

 

Related videos

follow us

WIN 2020


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation